Instant Clot-Forming and Antibacterial Wound Dressings: Technical Insights from the TXA–SNAP–Propolis Study

Study Background and Research Question

Uncontrolled hemorrhage and wound infection remain primary causes of mortality following traumatic injuries, accounting for a significant proportion of early deaths in both civilian and military settings. The challenge is twofold: achieving rapid hemostasis to prevent fatal blood loss, and simultaneously mitigating the risk of infection, which is heightened due to immune system compromise at the wound site. Tranexamic acid (TXA), a synthetic antifibrinolytic agent, has been widely used to limit fibrinolysis and stabilize clots, but integrating its clot-promoting ability with antimicrobial wound care remains an unmet need. This study, published by Nguyen et al. (reference study), addresses whether a bi-layer wound dressing combining TXA, nitric oxide (NO) donor S-nitroso-N-acetylpenicillamine (SNAP), and propolis can deliver both instant clotting and antibacterial protection.

Key Innovation from the Reference Study

The central innovation described by Nguyen et al. is the fabrication of a multi-functional wound dressing that unites three synergistic components:

• Tranexamic Acid (TXA): Incorporated as a clot-stabilizing antifibrinolytic agent to arrest fibrinolysis at the wound interface.
• Propolis: Serves as a natural, bioadhesive matrix with inherent antibacterial and anti-inflammatory properties, supporting local retention and activity of TXA.
• S-nitroso-N-acetylpenicillamine (SNAP): Embedded in a Carbosil® (polycarbonate urethane-silicone) base layer, SNAP gradually releases NO, known for its broad-spectrum antimicrobial activity and positive modulation of wound healing phases.

This bi-layer approach targets both immediate clot formation and bacterial load reduction, directly responding to the dual threats present in acute trauma injuries. The design ensures that TXA is localised at the wound surface, while NO release and propolis-derived effects underlie longer-term antimicrobial and anti-inflammatory outcomes.

Methods and Experimental Design Insights

The research team engineered the wound dressing with a strategic architecture:

• The wound-facing layer was constructed by suspending TXA in a resinous bed of propolis, with propolis content varied at 2.5%, 5.0%, and 7.5% (v/v).
• The base layer comprised SNAP distributed within a Carbosil® polymeric matrix, ensuring controlled NO release.

To evaluate the dressing’s efficacy:

• Clot Formation: Fibrin activation was quantified using a lactate dehydrogenase-based platelet adhesion assay, with SEM imaging to visualize fibrin network density.
• Antibacterial Performance: Reduction in colony-forming units (CFU) was tested against Staphylococcus aureus and multidrug-resistant Acinetobacter baumannii.

The variable concentration of propolis allowed the team to systematically optimize the balance between bioadhesion, clot stabilization, and antibacterial potency. Workflow parameters—such as the proportion of propolis, TXA application method, and NO donor incorporation—are critical for reproducibility and can inform future translational protocols.

Protocol Parameters

• TXA-propolis layer: Prepare with 2.5–7.5% (v/v) propolis; 7.5% yielded maximal fibrin activation in this study.
• NO donor loading: Disperse SNAP uniformly in Carbosil® base; verify steady NO release over the intended application period.
• Clotting assay timing: Measure fibrin activation and platelet adhesion within 15 minutes of dressing application to capture instant hemostatic effect.
• Antibacterial testing: Quantify CFU reduction using both Gram-positive and multidrug-resistant Gram-negative strains post-exposure to the dressing.
• Wound model: Ensure the wound-facing layer is in direct contact with the simulated or actual wound bed to localize TXA effect.

Core Findings and Why They Matter

The study’s findings provide strong evidence for the synergistic benefits of the TXA–SNAP–propolis dressing:

• Instant Hemostasis: The 7.5% propolis formulation, when combined with TXA, significantly increased fibrin activation within the first 15 minutes, as compared to controls (reference study).
• Clot Stability: SEM imaging revealed a denser, more stable fibrin network in the TXA-containing dressings, supporting the concept that antifibrinolytic agents can enhance mechanical integrity of the clot at the wound surface.
• Antibacterial Efficacy: Combined NO and propolis activity resulted in a 98.9 ± 1% reduction in S. aureus CFUs and 99.4 ± 1% reduction in multidrug-resistant A. baumannii, suggesting broad applicability for infection control in trauma settings.

These results are highly relevant for emergency care, military medicine, and pre-hospital trauma response, where immediate and multifunctional wound management is critical. The dual-action strategy—rapid clotting and sustained antimicrobial activity—addresses key clinical gaps that single-modality dressings cannot.

Comparison with Existing Internal Articles

Recent internal reviews expand on both the molecular and translational aspects of antifibrinolytic agents. For instance, “Tranexamic Acid in Hemostasis Research: Mechanisms and Advanced Protocols” delves into the molecular inhibition of fibrinolysis by TXA, providing context for the mechanism exploited in the bi-layer dressing. Meanwhile, “Instant Clot-Forming NO-Releasing Dressings with Tranexamic Acid” explores translational potential, paralleling the reference study's approach to integrating antifibrinolytic and antimicrobial strategies. The present study builds on these foundations by demonstrating how TXA, when spatially co-localized with NO donors and bioadhesive matrices, not only preserves clot integrity but also complements antimicrobial defense, offering a robust protocol for trauma wound management.

Limitations and Transferability

While the TXA–SNAP–propolis dressing demonstrates promising outcomes in controlled laboratory settings, several limitations merit consideration:

• In vivo validation: Most findings are based on ex vivo and in vitro assays. The dressing's performance in complex wound environments, such as heavily contaminated or highly exudative trauma wounds, remains to be determined.
• Component optimization: The precise ratios of TXA, propolis, and SNAP may require further adjustment for different wound types and patient populations.
• Long-term effects: The implications of sustained NO release and propolis exposure over extended periods need further investigation, including potential cytotoxicity and tissue compatibility.

Despite these gaps, the modular nature of the dressing design supports adaptation for a range of clinical and research contexts. However, transferability to chronic wounds or non-traumatic bleeding conditions should be approached cautiously and supported by additional studies.

Research Support Resources

To facilitate further research and protocol development, high-purity antifibrinolytic agents such as Tranexamic Acid (SKU B1858) are available for scientific workflows requiring precise inhibition of fibrinolysis. Researchers aiming to replicate or extend the findings of the TXA–SNAP–propolis study should select reagents with rigorous quality documentation. For deeper mechanistic understanding or advanced assay design, reviews such as “Tranexamic Acid in Hemostasis: Molecular Synergy and Research Design” provide valuable protocol guidance. APExBIO’s Tranexamic Acid, supplied with NMR and MSDS documentation, is suitable for both in vitro and animal model experimentation, enabling reproducible application in clotting and plasmin-induced neutrophil adherence assays. As always, these reagents are intended strictly for research purposes and not for clinical use.